| | By Darren Incorvaia The Trump administration has blocked access to multiple data repositories maintained by the National Institutes of Health for researchers in several countries, including a cancer statistics database used regularly by scientists in China. |
|
|
|
By Gabrielle Masson On Monday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on research grants. The NIH is now appealing. |
By Kevin Dunleavy President Donald Trump’s announcement on Wednesday that pharmaceuticals imported to the U.S. would be exempt from tariff payments brought a sigh of relief from major drugmakers. But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs. |
By Angus Liu Although President Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import levies remain a sword of Damocles creating anxiety among biopharma companies. Some industry leaders now fear that more than $100 billion in investments could leave the European Union. |
By Gabrielle Masson As President Donald Trump’s massive overhaul of federal agencies continues, several former FDA officials spoke about the potential ramifications for drug reviews and provided a look inside current FDA conditions. |
By Darren Incorvaia As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German research institute BioMed X is stepping in to offer a lifeline. The institute has opened a matchmaking program to align threatened NIH grants with potential new funders from the pharmaceutical industry. |
By Fraiser Kansteiner Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports. |
By Fraiser Kansteiner On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow. |
By Conor Hale Looking to get its earnings out early, PacBio posted preliminary revenue estimates this week ahead of its full quarterly report scheduled for May 8. |
By Andrea Park Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Senior Writer Paige Minemyer chats with Jason Oberfest, vice president of healthcare at Oura, to discuss how the company is approaching its push into healthcare. |
|
|---|
|
|
|
Wednesday, April 16, 2025 | 11am ET / 8am PT In today’s healthcare landscape, strategic partnerships between life sciences companies and health systems are crucial for innovation. In this webinar, we will explore the key challenges that life sciences organizations face and provide actionable insights to overcome them. Register now.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperAvoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
